925672-88-4

Basic information

• Product Name: 5-BROMO-2-CYANOBENZENEACETONITRILE
• Synonyms: 5-BROMO-2-CYANOBENZENEACETONITRILE
• CAS NO: 925672-88-4
• Molecular Formula: C₉H₅BrN₂
• Molecular Weight: 221.06
• Mol File: 925672-88-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 345.2°C at 760 mmHg
• Flash Point: 162.6°C
• Appearance: /
• Density: 1.58g/cm³
• Vapor Pressure: 6.25E-05mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-BROMO-2-CYANOBENZENEACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CYANOBENZENEACETONITRILE(925672-88-4)
• EPA Substance Registry System: 5-BROMO-2-CYANOBENZENEACETONITRILE(925672-88-4)

Safety Data

• RIDADR: 3439
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 925672-88-4(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-cyanobenzeneacetonitrile is a chemical compound with the molecular formula C9H5N2Br. It is a cyanide derivative with a bromo group attached to a benzene ring, and it is commonly used as an intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds. This chemical has a wide range of applications in the field of organic chemistry and is known for its role as a versatile building block in the production of various industrial and medicinal products. It is also used as a reagent in the preparation of other complex molecules and is a valuable tool in the development of new chemical processes and materials. Overall, 5-Bromo-2-cyanobenzeneacetonitrile is an important and versatile compound with numerous industrial and scientific applications.

InChI:InChI=1/C9H5BrN2/c10-9-2-1-8(6-12)7(5-9)3-4-11/h1-2,5H,3H2

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 105-34-0 methyl 2-cyanoacetate 
• 925672-87-3 C₁₁H₇BrN₂O₂ 

Downstream Products

• 925672-85-1 1,6-dibromoisoquinolin-3-amine 
• 501130-49-0 6-bromoisoquinoline-1,3(2H,4H)-dione 
• 925673-01-4 C₁₉H₁₇BrN₂O₂ 
• 925672-98-6 C₁₇H₁₅BrN₂O 

Relevant articles and documents

Nickel-Catalyzed Tandem Reaction of Functionalized Arylacetonitriles with Arylboronic Acids in 2-MeTHF: Eco-Friendly Synthesis of Aminoisoquinolines and Isoquinolones

The first example of the nickel-catalyzed tandem addition/cyclization of 2-(cyanomethyl)benzonitriles with arylboronic acids in 2-MeTHF has been developed, which provides the facile synthesis of aminoisoquinolines with good functional group tolerance under mild conditions. This chemistry has also been successfully applied to the synthesis of isoquinolones by the tandem reaction of methyl 2-(cyanomethyl)benzoates with arylboronic acids. The use of the bio-based and green solvent 2-MeTHF as the reaction medium makes the synthesis process environmentally benign. The synthetic utility of this chemistry is also indicated by the synthesis of biologically active molecules.

Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2)

Tyrosyl DNA phosphodiesterase II (TDP2) is a recently discovered enzyme that specifically repairs DNA damages induced by topoisomerase II (Top2) poisons and causes resistance to these drugs. Inhibiting TDP2 is expected to enhance the efficacy of clinically important Top2-targeting anticancer drugs. However, TDP2 as a therapeutic target remains poorly understood. We report herein the discovery of isoquinoline-1,3-dione as a viable chemotype for selectively inhibiting TDP2. The initial hit compound 43 was identified by screening our in-house collection of synthetic compounds. Further structure-activity relationship (SAR) studies identified numerous analogues inhibiting TDP2 in low micromolar range without appreciable inhibition against the homologous TDP1 at the highest testing concentration (111 μM). The best compound 64 inhibited recombinant TDP2 with an IC50 of 1.9 μM. The discovery of this chemotype may provide a platform toward understanding TDP2 as a drug target.

THIADIAZOLE MODULATORS OF PKB

The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the th